US7612114 — Selective estrogen receptor modulator
Method of Use · Assigned to Eisai R&D Management Co Ltd · Expires 2026-08-18 · 0y remaining
What this patent protects
This patent protects a compound represented by formula (I), a selective estrogen receptor modulator.
USPTO Abstract
The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; Râ² represents 1 to 4 independent hydrogen atoms and the like; and Râ³ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3523 |
— | elacestrant-hydrochloride |
U-3523 |
— | elacestrant-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.